Drug
Dexpramipexole clinical trials
Also written BIIB050 and KNS-760704.
- studies test it
- 19
- open now
- 0
- in phase 3
- 6
- first study started
- 2008
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
19 studies that test it; most in 2012 (5)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 4 |
| 2012 | 5 |
| 2014 | 2 |
| 2019 | 1 |
| 2023 | 3 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 7
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 2
Knopp Biosciences (12) · Areteia Therapeutics (5) · Virginia Commonwealth University (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Dexpramipexole is read from its arms, and is right about nine times in ten.
Testing it · 19
- Phase III Long-Term Extension Study With DexpramipexoleTerminatedPhase 3Areteia TherapeuticsNCT06388889Written as Dexpramipexole Dihydrochloride
- A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.TerminatedPhase 3Areteia TherapeuticsNCT05763121Written as Dexpramipexole Dihydrochloride
- A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)TerminatedPhase 3Areteia TherapeuticsNCT05813288Written as Dexpramipexole Dihydrochloride
- A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic AsthmaActive, not recruitingPhase 3Areteia TherapeuticsNCT05748600Written as Dexpramipexole Dihydrochloride
- A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPDActive, not recruitingPhase 2Areteia TherapeuticsNCT06533553Written as Dexpramipexole Dihydrochloride
- Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic AsthmaCompletedPhase 2Knopp BiosciencesNCT04046939Written as Dexpramipexole
- Phase 3 Extension Study of Dexpramipexole in ALSTerminatedPhase 3Knopp BiosciencesNCT01622088Written as Dexpramipexole
- Safety Study of R(+)Pramipexole to Treat Early Alzheimer's DiseaseCompletedPhase 2Virginia Commonwealth UniversityNCT01388478Written as R-pramipexole
- Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211)CompletedPhase 2Knopp BiosciencesNCT00931944Written as KNS-760704
- Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 2Knopp BiosciencesNCT00647296Written as Dexpramipexole 50 mg/day
- Phase 3 Study of Dexpramipexole in ALSCompletedPhase 3Knopp BiosciencesNCT01281189Written as Dexpramipexole
- Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and EosinophiliaCompletedPhase 2Knopp BiosciencesNCT02217332Written as dexpramipexole
- Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic SyndromeStatus unknownPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT02101138Written as Dexpramipexole
- Dexpramipexole Renal PK StudyCompletedPhase 1Knopp BiosciencesNCT01424176Written as Dexpramipexole (dose 1)
- Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)CompletedPhase 1Knopp BiosciencesNCT01511029Written as Dexpramipexole
- Dexpramipexole and Warfarin Drug Drug Interaction (DDI) StudyCompletedPhase 1Knopp BiosciencesNCT01597310Written as Dexpramipexole
- Study in Healthy Volunteers of the Bioavailability of Dexpramipexole Tablets and Food EffectsCompletedPhase 1Knopp BiosciencesNCT01607034Written as Dexpramipexole
- Dexpramipexole and Cimetidine Drug Drug Interaction (DDI)CompletedPhase 1Knopp BiosciencesNCT01536249Written as Dexpramipexole
- Dexpramipexole SAD/MAD StudyCompletedPhase 1Knopp BiosciencesNCT01449578Written as Dexpramipexole
Codes
What other systems call Dexpramipexole · ClinicalTrials.gg INT006880
- MeSH (NLM) D000097662DexpramipexoleConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) WI638GUS96DEXPRAMIPEXOLEConfirmed FDA, NLM, Wikidata
- Wikidata Q5268345dexpramipexoleConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169899DexpramipexoleOne source FDA
- DrugBank DB15130One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000097662 | Dexpramipexole | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | WI638GUS96 | DEXPRAMIPEXOLE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5268345 | dexpramipexole | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169899 | Dexpramipexole | One source FDA |
| DrugBank | DB15130 | — | One source Wikidata |
Also registered as dexpramipexole dihydrochloride (UNII 795J01AE70).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.